Drug intelligence / Profile preview

Qishu Tangshen Granules

Development stage: Unknown
Lead developer: China Academy of Chinese Medical Sciences
Modality: Small Molecules
Administration: Oral

Overview

Qishu Tangshen Granules is a Traditional Chinese Medicine (TCM) formulation developed by the China Academy of Chinese Medical Sciences Xiyuan Hospital. It is specifically designed for the treatment of diabetic kidney disease (DKD) in patients exhibiting the Qi and Yin deficiency pattern. The formulation is intended to tonify Qi and nourish Yin, addressing the underlying TCM pathological mechanisms of diabetic renal complications. It is currently being evaluated in Phase 2 clinical trials in China to determine its efficacy in reducing proteinuria and slowing the progression of kidney damage in adult patients with DKD.

Other names: Qishu Tangshen Keli

Beyond the preview

Go deeper on Qishu Tangshen Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qishu Tangshen Granules.

Explore the full profile